The goal of this prospective, multicenter, observational cohort study with longitudinal blood sampling and standardized neurological evaluation over 6 months is to identify biomarkers to predict the overall occurrence of chronic chemotherapy-induced peripheral neuropathy (CIPN, any grade), in each of two treatment subgroups (taxanes and oxaliplatin). It involves integration of clinical data and plasma multiomic biomarkers (proteomic + metabolomic panel) analyzed via supervised machine learning to identify predictive features of CIPN.
Patients who have received detailed information about the study and have signed, with the investigator, a consent form to participate in the study
Patients being treated for cancer at any stage of the disease and scheduled to receive chemotherapy including one (and only one) of the following molecules: paclitaxel, docetaxel, or oxaliplatin, for a planned duration of 9 weeks or more
Age > 18 years
Life expectancy > 3 months
Patients already suffering from neuropathy or chronic neurogenic pain
Patients with type 1 or type 2 diabetes (for more than 10 years for type 2 diabetes)
Patients who have already received neurotoxic cancer treatment including those in clinical trials
Patients receiving two of the study molecules simultaneously (only one study molecule is permitted, including in combination chemotherapy but that does not include another neurotoxic molecule)